医学
膜性肾病
危险分层
生物标志物
内科学
风险评估
免疫系统
风险因素
肾病
置信区间
肾小球肾炎
重症监护医学
梅德林
人口
疾病
胃肠病学
作者
Tianyu Zheng,Yuanyuan Du,Xuanli Tang,Xiang Shao,Lingli Chen,Shangbin Kao,Yuan Han Qin,Xuan Zhou,Xueqin Zhao,Haiyan Gao,Biao Huang
出处
期刊:
日期:2026-01-06
卷期号:150 (5): 1-9
摘要
INTRODUCTION: The utility of M-type phospholipase A2 receptor antibody (PLA2R-Ab) for risk stratification in membranous nephropathy (MN) remains suboptimal, while soluble T-cell immunoglobulin and mucin-domain containing-3 (sTim-3) has been confirmed as a critical immune regulator in kidney diseases. This study investigated the prognostic value of sTim-3 in PLA2R-associated MN (PMN) and the efficacy of its combination with PLA2R-Ab. METHODS: Serum PLA2R-Ab and sTim-3 levels were measured at baseline in 50 PMN patients using highly sensitive time-resolved fluorescence immunoassay (TRFIA) method. Patients were stratified into complete remission, partial remission, and no remission (NR) groups according to 12-month treatment outcomes. RESULTS: Prognostic cut-off discriminating NR from remission: sTim-3 = 17.63 ng/mL; PLA2R-Ab = 50 RU/mL (KDIGO high-risk threshold). The non-remission rate for patients with PLA2R-Ab <50 RU/mL was 23.58%, whereas the sTim-3 + PLA2R-Ab combination achieved 0%. Among 16 "high-risk" patients (PLA2R-Ab >50 RU/mL), sTim-3 demonstrated 93.75% accuracy in predicting outcomes. Remarkably, all 8 patients who achieved actual remission exhibited sTim-3 levels below 17.63 ng/mL. Double positivity (PLA2R-Ab >50 RU/mL and sTim-3 >17.63 ng/mL) identified a refractory subgroup with significantly poorer treatment response compared to other groups. CONCLUSION: sTim-3 serves as a complementary biomarker to PLA2R-Ab. Combined detection optimizes PMN risk stratification: PLA2R-Ab >50 RU/mL and sTim-3 >17.63 ng/mL indicates an immune-activated state requiring intensive immunosuppression, preventing overtreatment in PLA2R-Ab-high patients with favorable immune status.
科研通智能强力驱动
Strongly Powered by AbleSci AI